169 related articles for article (PubMed ID: 36641337)
21. Comparison of 18F-fluoro-L-DOPA, 18F-fluoro-deoxyglucose, and 18F-fluorodopamine PET and 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma.
Timmers HJ; Chen CC; Carrasquillo JA; Whatley M; Ling A; Havekes B; Eisenhofer G; Martiniova L; Adams KT; Pacak K
J Clin Endocrinol Metab; 2009 Dec; 94(12):4757-67. PubMed ID: 19864450
[TBL] [Abstract][Full Text] [Related]
22. Effects and safety of ¹³¹I-metaiodobenzylguanidine (MIBG) radiotherapy in malignant neuroendocrine tumors: results from a multicenter observational registry.
Yoshinaga K; Oriuchi N; Wakabayashi H; Tomiyama Y; Jinguji M; Higuchi T; Kayano D; Fukuoka M; Inaki A; Toratani A; Okamoto S; Shiga T; Ito YM; Nakajo M; Nakajo M; Kinuya S; ; ;
Endocr J; 2014; 61(12):1171-80. PubMed ID: 25214026
[TBL] [Abstract][Full Text] [Related]
23. Performance of
Han S; Suh CH; Woo S; Kim YJ; Lee JJ
J Nucl Med; 2019 Mar; 60(3):369-376. PubMed ID: 30030341
[TBL] [Abstract][Full Text] [Related]
24. 6-18F-fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to 123I-metaiodobenzyl-guanidine scintigraphy in the detection of extraadrenal and hereditary pheochromocytomas and paragangliomas: correlation with vesicular monoamine transporter expression.
Fottner C; Helisch A; Anlauf M; Rossmann H; Musholt TJ; Kreft A; Schadmand-Fischer S; Bartenstein P; Lackner KJ; Klöppel G; Schreckenberger M; Weber MM
J Clin Endocrinol Metab; 2010 Jun; 95(6):2800-10. PubMed ID: 20371665
[TBL] [Abstract][Full Text] [Related]
25. Systemic Radiopharmaceutical Therapy of Pheochromocytoma and Paraganglioma.
Carrasquillo JA; Chen CC; Jha A; Pacak K; Pryma DA; Lin FI
J Nucl Med; 2021 Sep; 62(9):1192-1199. PubMed ID: 34475242
[TBL] [Abstract][Full Text] [Related]
26. Detection and treatment of pheochromocytomas and paragangliomas: current standing of MIBG scintigraphy and future role of PET imaging.
Havekes B; Lai EW; Corssmit EP; Romijn JA; Timmers HJ; Pacak K
Q J Nucl Med Mol Imaging; 2008 Dec; 52(4):419-29. PubMed ID: 19088695
[TBL] [Abstract][Full Text] [Related]
27. Prognostic value of [
Takenaka J; Watanabe S; Abe T; Hirata K; Uchiyama Y; Kimura R; Shinohara N; Kudo K
Ann Nucl Med; 2023 Jan; 37(1):10-17. PubMed ID: 36301465
[TBL] [Abstract][Full Text] [Related]
28. I-131 Metaiodobenzylguanidine Therapy of Pheochromocytoma and Paraganglioma.
Carrasquillo JA; Pandit-Taskar N; Chen CC
Semin Nucl Med; 2016 May; 46(3):203-14. PubMed ID: 27067501
[TBL] [Abstract][Full Text] [Related]
29. A phase I clinical trial for [
Inaki A; Yoshimura K; Murayama T; Imai Y; Kuribayashi Y; Higuchi T; Jinguji M; Shiga T; Kinuya S
J Med Invest; 2017; 64(3.4):205-209. PubMed ID: 28954983
[TBL] [Abstract][Full Text] [Related]
30.
Krokhmal AA; Kwatra N; Drubach L; Weldon CB; Janeway KA; DuBois SG; Kamihara J; Voss SD
Pediatr Blood Cancer; 2022 Aug; 69(8):e29740. PubMed ID: 35484995
[TBL] [Abstract][Full Text] [Related]
31. Iodine -131 metaiodobenzylguanidine is an effective treatment for malignant pheochromocytoma and paraganglioma.
Safford SD; Coleman RE; Gockerman JP; Moore J; Feldman JM; Leight GS; Tyler DS; Olson JA
Surgery; 2003 Dec; 134(6):956-62; discussion 962-3. PubMed ID: 14668728
[TBL] [Abstract][Full Text] [Related]
32. Treatment of inoperable or metastatic paragangliomas and pheochromocytomas with peptide receptor radionuclide therapy using 177Lu-DOTATATE.
Zandee WT; Feelders RA; Smit Duijzentkunst DA; Hofland J; Metselaar RM; Oldenburg RA; van Linge A; Kam BLR; Teunissen JJM; Korpershoek E; Hendriks JM; Abusaris H; Slagter C; Franssen GJH; Brabander T; De Herder WW
Eur J Endocrinol; 2019 Jul; 181(1):45-53. PubMed ID: 31067510
[TBL] [Abstract][Full Text] [Related]
33. Genotype-Dependent Brown Adipose Tissue Activation in Patients With Pheochromocytoma and Paraganglioma.
Puar T; van Berkel A; Gotthardt M; Havekes B; Hermus AR; Lenders JW; van Marken Lichtenbelt WD; Xu Y; Brans B; Timmers HJ
J Clin Endocrinol Metab; 2016 Jan; 101(1):224-32. PubMed ID: 26574955
[TBL] [Abstract][Full Text] [Related]
34. Long-Term Outcomes of 125 Patients With Metastatic Pheochromocytoma or Paraganglioma Treated With 131-I MIBG.
Thorpe MP; Kane A; Zhu J; Morse MA; Wong T; Borges-Neto S
J Clin Endocrinol Metab; 2020 Mar; 105(3):e494-501. PubMed ID: 31614368
[TBL] [Abstract][Full Text] [Related]
35. Iodine-131 metaiodobenzylguanidine (I-131 MIBG) diagnosis and therapy of pheochromocytoma and paraganglioma: current problems, critical issues and presentation of a sample case.
Castellani MR; Aktolun C; Buzzoni R; Seregni E; Chiesa C; Maccauro M; Aliberti GL; Vellani C; Lorenzoni A; Bombardieri E
Q J Nucl Med Mol Imaging; 2013 Jun; 57(2):146-52. PubMed ID: 23822990
[TBL] [Abstract][Full Text] [Related]
36. Role of [68Ga]DOTANOC PET/computed tomography and [131I]MIBG scintigraphy in the management of patients with pheochromocytoma and paraganglioma: a prospective study.
Singh D; Shukla J; Walia R; Vatsa R; Paul N; Chhabra A; Nahar U; Singh H; Kumar R; Bhansali A; Rai Mittal B
Nucl Med Commun; 2020 Oct; 41(10):1047-1059. PubMed ID: 32732602
[TBL] [Abstract][Full Text] [Related]
37. 131I-MIBG therapy in metastatic phaeochromocytoma and paraganglioma.
Gedik GK; Hoefnagel CA; Bais E; Olmos RA
Eur J Nucl Med Mol Imaging; 2008 Apr; 35(4):725-33. PubMed ID: 18071700
[TBL] [Abstract][Full Text] [Related]
38. Comparison of metaiodobenzylguanidine scintigraphy with positron emission tomography in the diagnostic work-up of pheochromocytoma and paraganglioma: a systematic review.
Rufini V; Treglia G; Castaldi P; Perotti G; Giordano A
Q J Nucl Med Mol Imaging; 2013 Jun; 57(2):122-33. PubMed ID: 23822989
[TBL] [Abstract][Full Text] [Related]
39. High-specific-activity
Dillon JS; Bushnell D; Laux DE
Future Oncol; 2021 Apr; 17(10):1131-1141. PubMed ID: 33506713
[TBL] [Abstract][Full Text] [Related]
40. Response to targeted radionuclide therapy with [
Prado-Wohlwend S; Del Olmo-García MI; Bello-Arques P; Merino-Torres JF
Front Endocrinol (Lausanne); 2022; 13():957172. PubMed ID: 36339441
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
